Form 4: United Therapeutics CEO Executes Planned Stock Sale

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• The acquired shares were subsequently sold in multiple transactions on April 23, 2026.
• The sales were executed at weighted average prices ranging from $569.61 to $576.33 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned insider transaction that does not indicate a change in the company's fundamental outlook.

Positives

• The transactions were part of a pre-planned, systematic divestment strategy, which typically signals routine financial planning rather than a lack of confidence in the company.
• The CEO maintains a significant remaining beneficial ownership stake in the company, including 40,513 shares held directly and substantial holdings in various family trusts.

Negatives

• The transaction results in a reduction of the CEO's direct beneficial ownership of common stock.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, which may lead to further periodic selling pressure on the stock.

Future Outlook

The reporting person intends to continue selling shares under the established 10b5-1 plan until the end of 2026 or until the specified 1,734,410 options are exhausted.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are standard practice in the biotech industry for liquidity and diversification, and generally do not reflect negative sentiment regarding company performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard corporate governance practice for C-suite executives at large-cap pharmaceutical companies to avoid allegations of insider trading.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive wealth management strategies.

Stakeholder Impact

• Shareholders should view this as a planned liquidity event for the CEO rather than a signal of operational changes.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, 10b5-1, Stock Options, Biotech